Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn

Commercialisation

One of the key remits of the Centre is to increase commercialisation opportunities of research outputs. To this end we work closely with the RCSI Technology Transfer Office in the following areas:

 

Motoneuron degeneration

Commercialisation activities on research into treatment for motoneuron degeneration is funded through two main awards:

  • EI Technology Development Award - Systemic delivery of angiogenin protein for the treatment of ALS: Therapeutic modulation of angiogenin levels in the spinal cord
  • SFI Technology and Innovation Development Award, Feasibility - Systematic administration of amiloride for the treatment of motoneuron disorders

Alzheimer's Disease

  • Pfizer Medivation - Study to explore the mechanism of action of Dimebon in AD and other neurodegenerative disorder (focusing on cellular bioenergetics)
  • H. Lundbeck A/S

Multiplexing and work flow solutions

  • Research in collaboration with Luxcel aims to extend of the range of applications of the current Mitoxpress reagent, assist with development and validation of new Luxcel probes and the development of multiplexing and work flow solutions.

Epilepsy

Commercialisation activities on research into treatment for epilepsy include:

  • SFI Technology and Innovation Development Award, Feasability - Antagomirs for the treatment of epilepsy.
  • The team also holds intellectual property / patent protection around miRNA based inhibitors for epilepsy and P2X7 reveptors as targets for status epilepticus.